Cardioprotective and Anti-inflammatory Effects of FAM3D in Myocardial Ischemia-Reperfusion Injury

Human plasma samples from patients with acute myocardial infarction (AMI) were obtained at 14-28 days and 6 months after index event, as part of the OMEGA-REMODEL Trial [Heydari, B., et al., <em>Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial.</em> Circulation, 2016. <strong>134</strong>(5): p. 378-91]. Patients were enrolled across 3 tertiary-care centers in Boston, MA, with each of their Institutional Review Boards approving the study (Brigham and Women’s, Massachusetts General, and Beth Israel Deaconess Medical Center hospitals). All patients received standard medical therapy per discretion of their attending cardiologists. Please refer to Heydari et al. for inclusion and exclusion criteria, and study endpoints. The primary study endpoint was change in left ventricular end-systolic volume indexed to body surface area (LVESVI, mL/m2) by cardiac MRI over 6 months. Blood samples were anticoagulated with EDTA, and plasma immediately stored at -80C with minimal number of freeze-thaw cycles before proteomic analysis. An aptamer-based proteomics platform (version 3,Somalogic) was used to measure relative levels of 1,305 analytes, corresponding to 1,1272 unique human proteins.本数据集包含急性心肌梗死（acute myocardial infarction, AMI）患者在首次发病后14~28天及6个月时采集的血浆样本，该样本来源于OMEGA-REMODEL临床试验[Heydari B等，《Omega-3脂肪酸乙酯对急性心肌梗死后左心室重构的影响：OMEGA-REMODEL随机临床试验》，《循环》（Circulation），2016年，134(5)：378-391]。受试者招募于美国马萨诸塞州波士顿的3家三级医疗中心（tertiary-care centers），所有研究均获得各机构审查委员会（Institutional Review Boards）的批准，涉及的医院包括布里格姆妇女医院、麻省总医院及贝丝以色列女执事医疗中心。所有患者均按照接诊心血管专科医师的临床判断接受标准药物治疗。纳入排除标准及研究终点详情请参见Heydari等的相关研究。本研究的主要终点为：通过心脏磁共振成像（cardiac MRI）评估的、6个月内左心室收缩末期容积指数（left ventricular end-systolic volume indexed to body surface area, LVESVI，单位：mL/m²）的变化量。血液样本采用乙二胺四乙酸（EDTA）进行抗凝处理，血浆采集后立即置于-80℃低温冰箱保存，在进行蛋白质组学分析（proteomic analysis）前尽可能减少冻融循环（freeze-thaw cycles）次数。本研究采用基于适配体的蛋白质组学平台（aptamer-based proteomics platform，Somalogic第3版）对1305种分析物（analytes）的相对水平进行检测，这些分析物对应11272种独特的人类蛋白质。